Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metast… (NCT07517224) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
40 participantsStarted 2026-10-01
Plain-language summary
The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors.
The main questions it aims to answer are:
* Is an 8-week aerobic exercise program feasible in breast cancer survivors after the completion of chemotherapy?
* Is this 8-week aerobic exercise program beneficial for vascular function in breast cancer survivors?
Participants will:
* Begin an 8-week aerobic exercise program, three days per week, after the completion of chemotherapy.
* Visit our facility three times before the exercise program, 1 month after, and after the completion of the program.
* Complete questionnaires, physical functional tests, and body composition and vascular measurements at every visit.
Who can participate
Age range
18 Years – 70 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapies.
. Able to begin aerobic exercise within 4 weeks of the final chemotherapy cycle.
. Sedentary by self-reporting inactivity (\<90 min of moderate or vigorous exercise per week)
. Weight ≤154 kg
. Willing to complete all study activities
. Able to safely participate in moderate aerobic exercise.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Enrollment (Recruitment rate)
Timeframe: From enrollment to immediately after first visit
2
Participant adherence - Proportion of people considered adherent
Timeframe: From enrollment to the end of intervention at 8 weeks
3
Retention - Proportion of survivors who completed the study
Timeframe: From enrollment to the end of intervention at 8 weeks
4
Pulse Wave Velocity
Timeframe: From enrollment to the end of intervention at 8 weeks"
5
Aortic Blood Pressure
Timeframe: From enrollment to the end of intervention at 8 weeks
. Current pregnant and lactating patients. Must have completed lactation prior to study start.
. Metastatic disease.
. Diagnosed cardiovascular disease prior to the initiation of chemotherapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.
. History of prior chemotherapy received for other cancer diagnosis.